ABSTRACT
Aim of the study was to investigate Gastroprotective and anti-secretory effect of Pep-Up Tablet on pyloric ligation-induced gastric ulcer model in rats. Pep-Up Tablet is an Ayurvedic proprietary formulation which is manufactured and marketed by Vasu Healthcare Pvt. Ltd., Vadodara. The selected animals were divided into two groups and each group consisted of six animals. Group-I was considered as disease control and Group-II was as test drug (Pep-Up Tablet) treated group. Pep-Up Tablet (200 mg/kg/day, p.o.) was administered for 7 days by oral route in Group-II. Pep-Up Tablet was studied for its effect on ulcer index, gastric wall secretory parameters and mucin activity. Pretreatment of Pep-Up Tablet showed significant reduction in ulcer index, gastric acid secretion and pepsin activity. Pep-Up Tablet significantly increased mucin activity (TC:TP ratio) as well which was due to significant increase in the total carbohydrate content. From the available data of present study, it can be concluded that Pep-Up Tablet plays important role mainly on inhibition of acid secretion and in increase of mucin secretion which in turn enhances the stability of gastric mucosal barrier. Pep-Up Tablet provided significant gastric cytoprotection against pyloric ligation-induced gastric ulceration in rats.
ABSTRACT
The present study was designed to study the effect of SR 58611A, a selective beta 3-adrenoceptor agonist against gastric ulcers: pylorus ligation, water immersion plus restraint stress (WIRS), ethanol, aspirin-induced and on cysteamine-induced duodenal ulcers, in rats. SR 58611A (10 mg/kg, p.o.) was found to be effective in attenuating gastric ulceration and the results were comparable with those from standard cimetidine-treated group. Apart from reducing ulcer index, SR 58611A significantly decreased total acidity and thereby exhibited antisecretory activity in pylorus ligation model. SR 58611A showed significant reduction in ulcer index alongwith significant rise in the gastric wall mucus content in WIRS model. Further it showed significant cytoprotective activity against ethanol insult, that was evident from significant reduction in ulcer index. It showed significant reduction in gastric ulceration in aspirin-treated rats. The drug was found to be ineffective in inhibiting the cysteamine-induced duodenal ulcers as evident from the ulcer index and total lesion area parameters. It is concluded that SR 586111A possesses significant gastroprotective activity. This activity could be attributed to the inhibition of gastric acidity, increase in gastric wall mucus content and the reversal of gastric microvascular injury resulting into protection of the vascular integrity.